Fig. 1.
Proposed steps for the personalization of treatment in depression. Step 3 is shadowed as its possible clinical utility has not been investigated yet in the treatment of patients with depression.
PRS, polygenic risk scores; TDM, therapeutic drug monitoring; SSRIs, selective serotonin reuptake inhibitors; PMs, poor metabolizers; IMs, intermediate metabolizers; UMs, ultrarapid metabolizers.